공시 • Apr 23
Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in funding Sirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering. 공시 • Apr 22
Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbH Sirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements. 공시 • Apr 05
Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding On April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement. 공시 • Feb 02
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding Sirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval. 공시 • Jan 27
Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024 Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024. 공시 • Dec 12
Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326 Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability. 